MLAB Biosciences’ Scientific Advisory Board brings together distinguished leaders in neuromuscular research, translational medicine, drug development, and clinical practice. With extensive experience spanning academia, industry, and patient-centered innovation, the Board provides strategic insight to guide and accelerate the advancement of MLAB’s transformative therapies.
Edward M. Kaye, MD
Chair, Scientific Advisory Board
Dr. Ed Kaye has dedicated his career to advancing treatments for children with severe genetic diseases, contributing to the development of seven approved medicines that have transformed the lives of tens of thousands of patients. Trained in pediatrics, pediatric neurology, and biochemical genetics, he began his career on the research staff at Massachusetts General Hospital and Tufts Medical Center, later serving as Chief of Biochemical Genetics at the Children’s Hospital of Philadelphia and as a pediatric neurologist at Boston Children’s Hospital. He spent a decade at Genzyme, where he led clinical development for lysosomal storage and genetic neurological disorders. He later joined Sarepta Therapeutics, first as Chief Medical Officer and then as CEO, overseeing the approval of Exondys 51, the first FDA-approved therapy for Duchenne muscular dystrophy.
Dr. Kaye most recently served as CEO of Stoke Therapeutics and now leads Aurora Therapeutics as CEO. He also serves on the Boards of Directors at Stoke, Cytokinetics, Avidity Biosciences, and MassBio.
Kathryn R. Wagner, MD, PhD
Scientific Advisor
Dr. Kathryn Wagner, Professor Emerita of Neurology and Neuroscience at Johns Hopkins School of Medicine, has dedicated her career to advancing treatments for neurological and neuromuscular disorders. She earned her M.D. and Ph.D. in molecular neuroscience from the Johns Hopkins School of Medicine, where her thesis described the cloning and characterization of the 87 kD protein later named dystrophin. Following residency and fellowship training in neurology, neuromuscular, and neurogenetic disorders, she conducted postdoctoral research identifying the loss of myostatin in the mdx model of Duchenne muscular dystrophy and in an otherwise healthy human infant, discoveries that helped define the role of myostatin and related signaling molecules in muscle regeneration.
Dr. Wagner founded the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute, leading both clinical care and translational research for children and adults with neuromuscular diseases. She later served as Vice President and Global Head of Neuromuscular Diseases at Roche, where she led late-stage programs in DMD, SMA, gMG, and FSHD, achieving multiple regulatory approvals. Most recently, she was Vice President and Global Head of Translational Medicine, Neuroscience at Novartis, directing early-stage development across a broad portfolio. Dr. Wagner currently serves as Chair of TREAT-NMD, an international network dedicated to improving diagnosis, standards of care, and access to emerging therapies for neuromuscular diseases.
Peter B. Kang, MD
Scientific Advisor
Dr. Peter Kang is a pediatric neuromuscular neurologist and physician-scientist specializing in neuromuscular genetics and translational research. He has published extensively in those areas, and his work has been instrumental in advancing genetic discoveries and therapeutic development for muscular dystrophy and related disorders. He currently serves as Professor and Vice Chair of Research, Department of Neurology, and as Director of the Greg Marzolf Jr. Muscular Dystrophy Center at the University of Minnesota. Dr. Kang is also the Editor of Neurology® Genetics. Previously, he was Chief of the Division of Pediatric Neurology at the University of Florida, and earlier in his career, he served as Director of the Electromyography Laboratory at Boston Children’s Hospital.